A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Trillium Therapeutics Inc.
• Treatments: Immunoglobulin G; Nivolumab; Rituximab

Criteria

Inclusion Criteria:

1. Advanced measurable malignancy

2. Adequate hematologic status

3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1 prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will be considered a systemic therapy. Local radiation and topical agents are not systemic therapies.

4. Adequate coagulation function

5. Adequate hepatic function

6. Adequate renal function

Exclusion Criteria:

1. Known, current central nervous system disease involvement or untreated brain metastases

2. Allogeneic transplant within 30 days prior to the planned start of treatment or subjects with active graft-vs-host disease with the exception of Grade 1 skin involvement

3. History of hemolytic anemia or bleeding diathesis